Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Celltrion, Inc.
  6. News
  7. Summary
    A068270   KR7068270008

CELLTRION, INC.

(A068270)
  Report
End-of-day quote Korea Stock Exchange  -  05-19
145000.00 KRW   +2.84%
05/18Celltrion, Inc. authorizes a Buyback Plan.
CI
05/17Celltrion, Inc. announces an Equity Buyback for 500,000 shares.
CI
05/16Celltrion, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Three South Korean Firms to Manufacture Low-Cost Variants of Merck's COVID-19 Pill

01/21/2022 | 06:01am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
CELLTRION, INC. 2.84% 145000 End-of-day quote.-26.77%
HANMI PHARM. CO., LTD. 2.04% 300500 End-of-day quote.8.88%
KOSPI COMPOSITE INDEX 0.20% 2643.92 Real-time Quote.-11.35%
All news about CELLTRION, INC.
05/18Celltrion, Inc. authorizes a Buyback Plan.
CI
05/17Celltrion, Inc. announces an Equity Buyback for 500,000 shares.
CI
05/16Celltrion, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/12Celltrion's Net Profit Falls 39.2% in Q1; Shares Slip 6%
MT
04/28Celltrion To Enter U.S. Humira Biosimilar Market Following Patent Agreement With AbbVie
AQ
04/19Celltrion's CT-P6 Demonstrates Equivalent Safety, Efficacy With HERCEPTIN
AQ
04/18Celltrion Healthcare Starts Selling Chronic Inflammatory Disease Biosimilar Yuflyma in ..
MT
04/07Regeneron's Disclaimer Of Aflibercept Formulation Patent Causes PTAB Denial Of Institut..
AQ
04/05Celltrion Announces Agreement With Brazilian Government To Supply Infliximab Biosimilar
AQ
04/01Regeneron Disclaims An Aflibercept Formulation Patent In Response To Celltrion PGR
AQ
More news
Analyst Recommendations on CELLTRION, INC.
More recommendations
Financials
Sales 2022 2 145 B 1,68 B 1,68 B
Net income 2022 569 B 0,45 B 0,45 B
Net cash 2022 996 B 0,78 B 0,78 B
P/E ratio 2022 34,1x
Yield 2022 0,17%
Capitalization 20 047 B 15 744 M 15 744 M
EV / Sales 2022 8,88x
EV / Sales 2023 8,00x
Nbr of Employees 2 034
Free-Float 75,2%
Chart CELLTRION, INC.
Duration : Period :
Celltrion, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELLTRION, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Last Close Price 145 000,00 KRW
Average target price 194 520,50 KRW
Spread / Average Target 34,2%
EPS Revisions
Managers and Directors
Wu-Sung Ki Chief Executive Officer & Director
Ho-Seop Lee Finance Director
Jung-Jin Seo Chairman
Sung-Han Lee Head-Legal & Compliance Support
Dong-Il Kim Independent Director
Sector and Competitors
1st jan.Capi. (M$)
CELLTRION, INC.-26.77%15 744
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704
ICON PUBLIC LIMITED COMPANY-30.22%17 567